コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 he impact on the AF severity scale and 7-day ambulatory monitoring.
2 MI underwent a whole-night sleep study using ambulatory monitoring.
3 onjunction with behavioral stress testing or ambulatory monitoring.
4 majority of individuals undergoing long-term ambulatory monitoring.
5 es are higher on clinic measurements than on ambulatory monitoring.
6 rdiogram during an arrhythmic event or using ambulatory monitoring.
7 runs of NSVT, including 17 before implant on ambulatory monitoring, 44 after ICD implantation, and 22
13 three-generation pedigree, cardiac imaging, ambulatory monitoring, and clinical genetic testing with
14 surement, the use of home blood pressure and ambulatory monitoring, and restricted use of beta-blocke
19 with those without transient ischemia during ambulatory monitoring could be excluded with greater tha
23 during exercises confirms its viability for ambulatory monitoring, enabling continuous assessment of
24 ial infarction or unstable angina, underwent ambulatory monitoring, exercise treadmill testing and st
29 r correlate with cardiovascular outcome, and ambulatory monitoring is more accurate than both clinic
32 e clinic setting and elevated BP assessed by ambulatory monitoring, is associated with increased risk
35 ars, 74% women) completed a 5-day program of ambulatory monitoring of physical activity and symptoms
37 patients with COVID-19 allow clinical-grade ambulatory monitoring of the key symptoms of the disease
38 was judged to have equal test performance to ambulatory monitoring or if treatment was judged effecti
40 ession during treadmill exercise testing and ambulatory monitoring (r = 0.73, p = 0.0005 for heart ra
41 Monitor for Parkinson's Disease (MM4PD), an ambulatory monitoring system that used smartwatch inerti
44 m cholesterol and LDL cholesterol levels and ambulatory monitoring were repeated after 4 to 6 months
45 an 24 h blood pressure of >/=130/80 mm Hg by ambulatory monitoring within 1 week of randomisation) an